MA50464A - Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 - Google Patents

Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1

Info

Publication number
MA50464A
MA50464A MA050464A MA50464A MA50464A MA 50464 A MA50464 A MA 50464A MA 050464 A MA050464 A MA 050464A MA 50464 A MA50464 A MA 50464A MA 50464 A MA50464 A MA 50464A
Authority
MA
Morocco
Prior art keywords
muscarinic
receptor
positive allosteric
allosteric modulators
amides used
Prior art date
Application number
MA050464A
Other languages
English (en)
Inventor
Renny Abraham
Shankar Reddy Gagginapally
Venkateswarlu Jasti
Durga Malleshwari Kancharla
Abdul Rasheed Mohammed
Ramakrishna Nirogi
Santosh Kumar Pandey
Anil Karbhari Shinde
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MA50464A publication Critical patent/MA50464A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050464A 2017-10-27 2018-10-26 Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 MA50464A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741038173 2017-10-27

Publications (1)

Publication Number Publication Date
MA50464A true MA50464A (fr) 2021-06-02

Family

ID=64362593

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050464A MA50464A (fr) 2017-10-27 2018-10-26 Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1

Country Status (16)

Country Link
US (1) US11278530B2 (fr)
EP (1) EP3700895B1 (fr)
JP (1) JP7110338B2 (fr)
KR (1) KR102406885B1 (fr)
CN (1) CN111278814B (fr)
AU (1) AU2018354969B2 (fr)
BR (1) BR112020008050A2 (fr)
CA (1) CA3078164C (fr)
EA (1) EA202090995A1 (fr)
IL (1) IL273885B (fr)
MA (1) MA50464A (fr)
MX (1) MX2020004339A (fr)
NZ (1) NZ763341A (fr)
SG (1) SG11202003471XA (fr)
WO (1) WO2019082140A1 (fr)
ZA (1) ZA202002058B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017220539A1 (de) 2017-11-17 2019-05-23 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät
US11970483B2 (en) * 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
WO2020086864A1 (fr) 2018-10-24 2020-04-30 Vanderbilt University Modulateurs allostériques positifs du récepteur d'acétylcholine muscarinique m1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754220B2 (en) * 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
BR112012014180A2 (pt) 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
WO2011149801A1 (fr) 2010-05-28 2011-12-01 Merck Sharp & Dohme Corp. Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1
US8815902B2 (en) * 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
EP2821401B1 (fr) * 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Composés de dihydroquinolinone en tant que modulateurs du récepteur muscarinique m1
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015080904A1 (fr) * 2013-11-27 2015-06-04 Vanderbilt University Analogues substitués du 4-benzyl-3,4-dihydro-2h-benzo[b] [1,4] oxazine-2-carboxamide, utilisés comme modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
WO2015110370A1 (fr) * 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Dérivés de fluoro-naphtyle
WO2016009297A1 (fr) 2014-07-18 2016-01-21 Pfizer Inc. Dérivés de la pyridine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
SMT201900213T1 (it) 2015-06-08 2019-05-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
EP3347349B1 (fr) 2015-09-10 2019-09-18 Suven Life Sciences Limited Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
WO2017123482A1 (fr) 2016-01-14 2017-07-20 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 de dihydropyridoquinazoline
EP3416639B1 (fr) * 2016-02-16 2022-06-08 Vanderbilt University Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
WO2017155816A1 (fr) 2016-03-09 2017-09-14 Merck Sharp & Dohme Corp. Composés quinazoline utiles en tant que modulateurs allostériques positifs du récepteur m1
EP3428150B1 (fr) * 2016-03-11 2023-07-12 Takeda Pharmaceutical Company Limited Composé cyclique aromatique ayant une activité modulatrice allostérique positive sur le récepteur cholinergique de la muscarine m1
SMT202000554T1 (it) * 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
US10899759B2 (en) * 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
PT3643718T (pt) * 2017-06-20 2023-10-26 Takeda Pharmaceuticals Co Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
WO2019077517A1 (fr) * 2017-10-18 2019-04-25 Suven Life Sciences Limited Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MX2021004471A (es) * 2018-10-17 2021-08-24 Suven Life Sciences Ltd Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
US20200131180A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US20200131159A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Also Published As

Publication number Publication date
MX2020004339A (es) 2020-08-03
KR20200074177A (ko) 2020-06-24
US20200297703A1 (en) 2020-09-24
AU2018354969B2 (en) 2020-09-17
BR112020008050A2 (pt) 2020-11-03
EA202090995A1 (ru) 2020-07-15
NZ763341A (en) 2023-03-31
IL273885B (en) 2021-01-31
CA3078164A1 (fr) 2019-05-02
CN111278814B (zh) 2022-10-28
EP3700895A1 (fr) 2020-09-02
EP3700895B1 (fr) 2021-09-22
ZA202002058B (en) 2021-04-28
CA3078164C (fr) 2022-11-15
JP7110338B2 (ja) 2022-08-01
WO2019082140A1 (fr) 2019-05-02
CN111278814A (zh) 2020-06-12
IL273885A (en) 2020-05-31
JP2021500338A (ja) 2021-01-07
AU2018354969A1 (en) 2020-04-23
US11278530B2 (en) 2022-03-22
SG11202003471XA (en) 2020-05-28
KR102406885B1 (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
MA44253A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
MA45463A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
HUE053586T2 (hu) Muszkarin M1 receptor pozitív alloszterikus modulátorok
EP3347372A4 (fr) Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
MA50464A (fr) Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA46722A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
MA56196A (fr) Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b
MA47127A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
EP3758704A4 (fr) Modulateurs de l'expression d'irf4
MA47126A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
EP3544961A4 (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA52286A (fr) Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine
HUE063823T2 (hu) Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként
MA51036A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
EP3758494A4 (fr) Promédicaments à base d'amide de modulateurs de récepteur nucléaire de petites molécules
HUE047056T2 (hu) Fluoroindol-származékok mint muskarin M1 receptor pozitív alloszterikus modulátorok
MA50402A (fr) Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA51037A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
PL3431106T3 (pl) Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
MA53917A (fr) Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
MA50806A (fr) Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
EP3621951A4 (fr) Diarylurées en tant que modulateurs allostériques de cb1
EP3463342A4 (fr) Associations de modulateurs du récepteur des oestrogènes
HUE053734T2 (hu) 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
EP3560927A4 (fr) Dérivé d'azépine agissant en tant que modulateur du récepteur 5-ht7